Alvotech Operating Income Over Time
| ALVO Stock | USD 4.06 0.05 1.22% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alvotech Performance and Alvotech Correlation. Will Biotechnology sector continue expanding? Could Alvotech diversify its offerings? Factors like these will boost the valuation of Alvotech. If investors know Alvotech will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alvotech data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.58) | Earnings Share 0.23 | Revenue Per Share | Quarterly Revenue Growth 0.106 | Return On Assets |
Understanding Alvotech requires distinguishing between market price and book value, where the latter reflects Alvotech's accounting equity. The concept of intrinsic value - what Alvotech's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alvotech's price substantially above or below its fundamental value.
Understanding that Alvotech's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alvotech represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alvotech's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Alvotech and related stocks such as Tilray Inc, Phibro Animal Health, and Evotec SE ADR Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TLRY | (98.5 K) | (98.5 K) | (45.3 K) | (45.3 K) | (2.7 M) | (836.2 K) | (1 M) | (9.6 M) | (138.9 M) | (104 M) | (159.6 M) | (769.5 M) | (1.8 B) | (238.1 M) | (3.1 B) | (2.8 B) | (2.7 B) |
| PAHC | 15.7 M | 49.3 M | 56.7 M | 63.8 M | 87.7 M | 85.7 M | 97.9 M | 98.9 M | 73.3 M | 69.2 M | 74.9 M | 79 M | 71.8 M | 53.3 M | 110.5 M | 127 M | 133.4 M |
| EVO | (12.7 M) | 5.2 M | (3.2 M) | (21.4 M) | (6.4 M) | 11.6 M | 31.3 M | 37.5 M | 77.5 M | 62.6 M | 48.6 M | 41 M | 20.9 M | (107.1 M) | (142.5 M) | (163.9 M) | (155.7 M) |
| UFPT | 1.3 M | 15.7 M | 16.7 M | 17.4 M | 11.6 M | 11.7 M | 12.2 M | 11.7 M | 19.6 M | 24.7 M | 16.7 M | 21.2 M | 55.4 M | 57.7 M | 80.9 M | 93 M | 97.7 M |
| PGNY | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (11 M) | (3.5 M) | 9.7 M | 8.3 M | 32.3 M | 23.3 M | 62.2 M | 67.5 M | 77.6 M | 81.5 M |
| SEM | 119.1 M | 310.7 M | 336.9 M | 301.4 M | 284.5 M | 274.8 M | 299.8 M | 355.9 M | 417.3 M | 471.9 M | 567.7 M | 713.8 M | 403.3 M | 554.9 M | 268.3 M | 334.6 M | 373.7 M |
| BHVN | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (114.5 M) | (218.9 M) | (567.9 M) | (436.1 M) | (885.1 M) | (796.6 M) | (756.8 M) |
| COLL | (16 M) | (16 M) | (16 M) | (16 M) | (17.7 M) | (26.9 M) | (94.1 M) | (75.4 M) | (20.7 M) | (23.7 M) | 56.2 M | 17.6 M | 33.3 M | 167 M | 169.9 M | 195.4 M | 205.1 M |
| HROW | (46.2 K) | (939 K) | (4.2 M) | (7.7 M) | (10.1 M) | (14.8 M) | (15.9 M) | (12.2 M) | (5.2 M) | (4.8 M) | 385 K | 1.6 M | 1.9 M | 431 K | 8.8 M | 10.1 M | 10.7 M |
Alvotech and related stocks such as Tilray Inc, Phibro Animal Health, and Evotec SE ADR Operating Income description
Operating Income is the amount of profit realized from Alvotech operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Alvotech is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
Check out Alvotech Performance and Alvotech Correlation. To learn how to invest in Alvotech Stock, please use our How to Invest in Alvotech guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Alvotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.